HEALTHCARE UPDATE
FDA Approves Bepirovirsen for Selected Adults With Chronic Hepatitis B
The FDA approved Hibsago (bepirovirsen) on October 20, 2026 for a defined group of adults with chronic hepatitis B, in combination with existing antiviral therapy.
Eligibility and Safety Monitoring
The indication covers adults without cirrhosis who have taken hepatitis B antivirals for at least six months, have suppressed virus levels and have hepatitis B surface antigen (HBsAg) of 3,000 IU/mL or less on FDA-authorized testing. The FDA also authorized a companion assay to help select and monitor patients.
The medicine carries a boxed warning for serious liver reactions and low platelet counts. Regular blood testing and clinical follow-up are important. The announcement does not establish access or insurance coverage outside the United States, or mean patients should stop existing medication themselves.
Sources: [1]
Records for a Specialist Review
A records summary can bring together antiviral treatment history, recent laboratory reports and assessments of liver health. The treating team can explain how any new option relates to the individual case.
Sources and data notes
- FDA: approval of Hibsago for certain adults with chronic hepatitis B
Original FDA announcement published October 20, 2026; event October 20; checked October 21. US approval for a defined population, with existing antivirals and safety monitoring. Record-preparation wording is our editorial interpretation. No response rates or dosing instructions republished.
Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.